Inka Health's Analytical Achievements for AstraZeneca Canada Highlighted at ISPOR 2025

Onco-Innovations Limited's subsidiary, Inka Health Corp., has completed important analytical work for AstraZeneca Canada, making strides in pharmaceutical evidence generation. The work under the AZ Services Agreement has resulted in significant insights for regulatory evaluation and market access strategies using real-world data.

Two major studies stemming from this work will be presented at ISPOR 2025 in Montréal. The first study addresses bias in real-world evidence, showing how transportability analysis can improve data application across various populations. The second reviews how real-world evidence is used in drug submissions in Canada, highlighting its impact on regulatory processes.

These developments enhance Inka Health's SynoGraph analytics platform, which incorporates advanced causal inference techniques. The collaboration with AstraZeneca reinforces Inka Health's leadership in this field, with their methodologies set to feature prominently at the upcoming ISPOR conference.